EDK Editome Disease Knowledgebase

  1. Home
  2. Editing sites

Editing Sites

Gene symbol Position (hg19) Position (hg38) Disease E-level Editing effect Enzyme Phenotype Molecular Consequence PMID
HNRPLL chr2:38793330 chr2:38566188 Presence ADARs-mediated RNA editing of the HNRPLL pre-mRNA determined its splicing pattern RNA editing of HNRPLL generates a novel splicing variant linked to cell proliferation Alternative splicing
HNRPLL chr2:38793318 chr2:38566176 Presence ADARs-mediated RNA editing of the HNRPLL pre-mRNA determined its splicing pattern RNA editing of HNRPLL generates a novel splicing variant linked to cell proliferation Alternative splicing
HNRPLL chr2:38793328 chr2:38566186 Presence ADARs-mediated RNA editing of the HNRPLL pre-mRNA determined its splicing pattern RNA editing of HNRPLL generates a novel splicing variant linked to cell proliferation Alternative splicing
FLNA chrX:154000000 chrX:154771725 Presence Lack of FLNA editing induces elevated myosin phosphorylation, absence of FLNA editing increases smooth muscle contraction FLNA RNA-editing mice show diastolic hypertension NA
PDE8A chr15:85639984 chr15:85096753 Increasing NA RNA-editing providing a marker for discriminating between suicides and control groups NA
PDE8A chr15:85640002 chr15:85096771 Increasing NA RNA-editing providing a marker for discriminating between suicides and control groups NA
COG3 chr13:46090371 chr13:45516236 Presence NA Over-editing (>40%) at the COG3 I/V site with a worse prognosis in GBM patients Recoding
PDE8A chr15:85639950 chr15:85096719 Increasing RNA-editing regulate the PDE8A1 expression RNA editing play an important role in the initiation and propagation of SLE pathogenesis mRNA expression change
PDE8A chr15:85639951 chr15:85096720 Increasing RNA-editing regulate the PDE8A1 expression RNA editing play an important role in the initiation and propagation of SLE pathogenesis mRNA expression change
PDE8A chr15:85639981 chr15:85096750 Decreacing RNA-editing regulate the PDE8A1 expression RNA editing play an important role in the initiation and propagation of SLE pathogenesis mRNA expression change
PDE8A chr15:85639983 chr15:85096752 Decreacing RNA-editing regulate the PDE8A1 expression RNA editing play an important role in the initiation and propagation of SLE pathogenesis mRNA expression change
PDE8A chr15:85639984 chr15:85096753 Decreacing RNA-editing regulate the PDE8A1 expression RNA editing play an important role in the initiation and propagation of SLE pathogenesis mRNA expression change
XIAP chrX:123042943 chrX:123909093 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123042979 chrX:123909129 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123043064 chrX:123909214 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123044464 chrX:123910614 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123044465 chrX:123910615 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123044532 chrX:123910682 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123044553 chrX:123910703 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123044558 chrX:123910708 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123044559 chrX:123910709 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123045113 chrX:123911263 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123045132 chrX:123911282 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123045138 chrX:123911288 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123045142 chrX:123911292 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123045170 chrX:123911320 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123045172 chrX:123911322 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123046591 chrX:123912741 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123046596 chrX:123912746 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123046599 chrX:123912749 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123046644 chrX:123912794 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123046720 chrX:123912870 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047048 chrX:123913198 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047126 chrX:123913276 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047165 chrX:123913315 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047169 chrX:123913319 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047170 chrX:123913320 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047173 chrX:123913323 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047181 chrX:123913331 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047240 chrX:123913390 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047241 chrX:123913391 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047270 chrX:123913420 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
XIAP chrX:123047285 chrX:123913435 Presence Exerts a negative regulation on the expression of XIAP protein products Edited XIAP suppressed the XIAP-dependent apoptotic response protein products expression change
MDM2 chr12:69237004 chr12:68843224 Presence Exerts a negative regulation on the expression of MDM2 protein products Edited MDM2 suppressed the MDM2-dependent apoptotic response protein products expression change
MDM2 chr12:69237475 chr12:68843695 Presence Exerts a negative regulation on the expression of MDM2 protein products Edited MDM2 suppressed the MDM2-dependent apoptotic response protein products expression change
MDM2 chr12:69237509 chr12:68843729 Presence Exerts a negative regulation on the expression of MDM2 protein products Edited MDM2 suppressed the MDM2-dependent apoptotic response protein products expression change
MDM2 chr12:69237510 chr12:68843730 Presence Exerts a negative regulation on the expression of MDM2 protein products Edited MDM2 suppressed the MDM2-dependent apoptotic response protein products expression change
MDM2 chr12:69237519 chr12:68843739 Presence Exerts a negative regulation on the expression of MDM2 protein products Edited MDM2 suppressed the MDM2-dependent apoptotic response protein products expression change
PINK1 chr1:20975546 chr1:20649053 Presence RNA-editing technology recodes the mutation in PINK1(W437X) to rescue the PINK1/Parkin-mediated mitophagy. Repair mitophagy Recoding
CTSS chr1:150703607 chr1:150731131 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703612 chr1:150731136 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703613 chr1:150731137 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703619 chr1:150731143 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703620 chr1:150731144 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703634 chr1:150731158 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703647 chr1:150731171 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703661 chr1:150731185 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703672 chr1:150731196 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703676 chr1:150731200 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703679 chr1:150731203 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703691 chr1:150731215 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703696 chr1:150731220 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703697 chr1:150731221 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703698 chr1:150731222 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703701 chr1:150731225 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703706 chr1:150731230 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703715 chr1:150731239 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703716 chr1:150731240 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703720 chr1:150731244 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703745 chr1:150731269 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703752 chr1:150731276 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703764 chr1:150731288 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703787 chr1:150731311 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703812 chr1:150731336 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703826 chr1:150731350 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703838 chr1:150731362 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703850 chr1:150731374 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150703860 chr1:150731384 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704418 chr1:150731942 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704443 chr1:150731967 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704476 chr1:150732000 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704481 chr1:150732005 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704483 chr1:150732007 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704486 chr1:150732010 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704492 chr1:150732016 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704499 chr1:150732023 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704633 chr1:150732157 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704636 chr1:150732160 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704653 chr1:150732177 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
CTSS chr1:150704654 chr1:150732178 Presence RNA-editing in the CTSS 3'UTR can knockdown the CTSS mRNA expression and deficiency of cathepsin S reduces atherosclerosis and angiogenesis in vivo. Reduce atherosclerosis and angiogenesis mRNA stability change
COPA chr1:160272028 chr1:160302238 Decrease The hyperediting of COPA are closely associated with HCC pathogenesis. Affect tumor pathgenesis Recoding
WT1 chr11:32417945 chr11:32396399 Presence WT1 mutations affect the zinc finger (ZnF) domains in Wilms tumor and acute myeloid leukemia (AML). Induce mutation of wilms tumor and acute myeloid leukemia Recoding
SLC1A2 chr11:35312236 chr11:35290689 Presence RNA editing results in premature termination of transcription and reduces levels of EAAT2 glutamate transporter which have been observed in ALS. Affect disease processing Alternative splicing
GRIA4 chr11:105804694 chr11:105933968 Decrease The reduced editing at the R/G site of glutamate receptor subunits (GluRs) can limit the progression of cell death and prolonged suppression of GluR function in later stages may hinder synaptic plasticity. Promote recovery Recoding
PTPN6 chr12:7061118 chr12:6951955 Presence RNA editing results that aberrant splicing within the N-SH2 domain leading to retention of intron 3 in PTPN6, and involvement of processing in leukemogenesis. Affect disease processing Alternative splicing
GLI1 chr12:57864626 chr12:57470843 Presence RNA editing enhances a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance. Increase RNA editing level in disease Recoding
TPH2 chr12:72343387 chr12:71949607 Presence RNA editing is shown to inhibit the enzymatic activity of both TPH2 splice variants, the complex fine-tuning of central nervous system 5-HT biosynthesis by TPH2 alternative splicing and RNA editing. Affect disease processing Alternative splicing
TPH2 chr12:72366380 chr12:71972600 Presence RNA editing is shown to inhibit the enzymatic activity of both TPH2 splice variants, the complex fine-tuning of central nervous system 5-HT biosynthesis by TPH2 alternative splicing and RNA editing. Affect disease processing Alternative splicing
TPH2 chr12:72416259 chr12:72022479 Presence RNA editing is shown to inhibit the enzymatic activity of both TPH2 splice variants, the complex fine-tuning of central nervous system 5-HT biosynthesis by TPH2 alternative splicing and RNA editing. Affect disease processing Alternative splicing
TPH2 chr12:72425054 chr12:72031274 Presence RNA editing is shown to inhibit the enzymatic activity of both TPH2 splice variants, the complex fine-tuning of central nervous system 5-HT biosynthesis by TPH2 alternative splicing and RNA editing. Affect disease processing Alternative splicing
EDNRB chr13:78475194 chr13:77901059 Presence ETB proteins are functionally altered by mutation that may lead to HSCR. Induce disease Recoding
NEIL1 chr15:75638978 chr15:75346637 Increase The edited NEIL1 transcripts significantly enhances the growth of tumor cells in comparison with the transfection of the unedited transcripts. Increase RNA editing level in disease Recoding
ARPIN chr15:90444654 chr15:89901422 Presence RNA editing of ARPIN is edQTL of rs2028299 which associated with type 2 diabetes. Promote the disease risk NA
ARPIN chr15:90444708 chr15:89901476 Presence RNA editing of ARPIN is edQTL of rs2028299 which associated with type 2 diabetes. Promote the disease risk NA
NF1 chr17:29560055 chr17:31233037 Increase Inappropriately high levels of NF1 mRNA editing play a role in NF1 tumorigenesis and that editing may result in the functional equivalent of biallelic inactivation of the NF1 tumor suppressor. Increase RNA editing level in disease Recoding
LDLR chr19:11221338 chr19:11110662 Presence Skipping of exon 8 or the use of a novel cryptic acceptor splice site in exon 8 with a frameshift and premature stop codon leads to a marked reduction in LDL-R protein expressed in monocytes obtained from the familial hypercholesterolemia patient. Reduce hypercholesterolemia Alternative splicing
RHOQ chr2:46803740 chr2:46576601 Increase Recurrence is more frequently in patients with tumors having edited RHOQ transcripts. Promote recurrence Recoding
BLCAP chr20:36147532 chr20:37519130 Decrease NA Reduce RNA editing in disease Recoding
BLCAP chr20:36147562 chr20:37519160 Decrease NA Reduce RNA editing editing in disease Recoding
BLCAP chr20:36147562 chr20:37519160 Decrease NA Reduce RNA editing editing in disease Recoding
BLCAP chr20:36147572 chr20:37519170 Decrease NA Reduce RNA editing in disease mRNA expression change
BLCAP chr20:36147572 chr20:37519170 Decrease NA Reduce RNA editing in disease mRNA expression change
BLCAP chr20:36147572 chr20:37519170 Decrease NA Reduce RNA editing in disease mRNA expression change
BLCAP chr20:36147583 chr20:37519181 Decrease NA Reduce RNA editing in disease Recoding
BLCAP chr20:36147583 chr20:37519181 Decrease NA Reduce RNA editing in disease Recoding
BLCAP chr20:36147583 chr20:37519181 Decrease NA Reduce RNA editing in disease Recoding
BLCAP chr20:36147635 chr20:37519233 Decrease NA Reduce RNA editing in disease Recoding
BLCAP chr20:36147635 chr20:37519233 Decrease NA Reduce RNA editing in disease Recoding
BLCAP chr20:36147635 chr20:37519233 Decrease NA Reduce RNA editing in disease Recoding
GRIK1 chr21:21953743 chr21:20581430 Similar The significant increase in GluR5-editing efficiency in the temporal cortex tissue is an essential part of the pathogenesis of epilepsy. Unrelated Recoding
GRIK1 chr21:21953743 chr21:20581430 Decrease The editing of the ionotropic KAR is decreased at both GluK1 and GluK2 Q/R sites in the epicenter of the lesion. Reduce RNA editing in disease Recoding
FLNB chr3:58141791 chr3:58156064 Presence The hyperediting of FLNB are closely associated with HCC pathogenesis. Increase RNA editing level in disease Recoding
FLNB chr3:58141791 chr3:58156064 Presence The hyperediting patterns of FLNB might play a role in ESCC progression. Induce malignant phenotypes during tumor progression Recoding
IGFBP7 chr4:57976286 chr4:57110120 Increase The hyperediting patterns of FLNB might play a role in ESCC progression. Promote tumor cell apoptosis Recoding
IGFBP7 chr4:57976286 chr4:57110120 Decrease Inadequate A-to-I editing of IGFBP7 may be used by tumor cells to escape cellular control of proliferation. Promote tumor cell proliferation Recoding
IGFBP7 chr4:57976286 chr4:57110120 Decrease Inadequate A-to-I editing of IGFBP7 may be used by tumor cells to escape cellular control of proliferation. Promote tumor cell proliferation Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Promote neurodegenerative processes Recoding
GRIA2 chr4:158284670 chr4:157363518 Increase Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Promote cataract occurrence Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Affect disease processing Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Reduce RNA editing in disease Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Reduce RNA editing in disease Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Reduce RNA editing in disease Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Promote apoptpsis Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Reduce RNA editing in disease Recoding
GRIA2 chr4:158284670 chr4:157363518 Similar Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Unrelated Recoding
GRIA2 chr4:158284670 chr4:157363518 Increase Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Reduce RNA editing in disease Recoding
GRIA2 chr4:158284670 chr4:157363518 Decrease Deficiency of RNA editing in Q/R site of the GluA2 induces the loss of Ca2+ homeostasis. Reduce RNA editing in disease Recoding
DHFR chr5:79923329 chr5:80627510 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923359 chr5:80627540 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923360 chr5:80627541 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923366 chr5:80627547 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923368 chr5:80627549 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923378 chr5:80627559 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923393 chr5:80627574 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923402 chr5:80627583 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923423 chr5:80627604 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923424 chr5:80627605 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923430 chr5:80627611 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923432 chr5:80627613 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923445 chr5:80627626 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923919 chr5:80628100 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923926 chr5:80628107 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923943 chr5:80628124 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923955 chr5:80628136 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923957 chr5:80628138 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923960 chr5:80628141 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923966 chr5:80628147 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923973 chr5:80628154 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923990 chr5:80628171 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79923998 chr5:80628179 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79924006 chr5:80628187 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
DHFR chr5:79924012 chr5:80628193 Increase ADAR1 positively regulates the expression of DHFR by editing the miR-25-3p and miR-125a-3p binding sites in the 3'UTR of DHFR, enhancing cellular proliferation and resistance to methotrexate. Promote tumor cell proliferation mRNA expression change
GRIK2 chr6:102372589 chr6:101924714 Similar The significant increase in GluR5-editing efficiency in the temporal cortex tissue is an essential part of the pathogenesis of epilepsy. Unrelated NA
GRIK2 chr6:102372589 chr6:101924714 Decrease The editing of the ionotropic KAR is decreased at both GluK1 and GluK2 Q/R sites in the epicenter of the lesion. Reduce RNA editing in disease Recoding
GRIK2 chr6:102372589 chr6:101924714 Decrease The I/V site was showed a strong downregulation that persisted through the observational period in Spinal Cord Injury. Reduce RNA editing in disease Recoding
GRIK2 chr6:102372589 chr6:101924714 Decrease The I/V site was showed a strong downregulation that persisted through the observational period in Spinal Cord Injury. Reduce RNA editing in disease Recoding
SLC22A3 chr6:160769665 chr6:160348633 Presence RNA editing results in premature termination of transcription and reduces levels of EAAT2 glutamate transporter which have been observed in ALS. Affect disease processing Recoding
PODXL chr7:131194314 chr7:131509555 Absence RNA editing confers a loss-of-function phenotype that neutralizes the tumorigenic ability of the unedited PODXL. Reduce tumorigenic ability Recoding
AZIN1 chr8:103841638 chr8:102829410 Presence Edited AZIN1 promotes cell proliferation and possibly the HCC onset and progression. Promote tumor cell proliferation Recoding
AZIN1 chr8:103841638 chr8:102829410 Presence The edited AZIN1 conferred gain-of-function phenotypes that are manifested by more aggressive behaviors during ESCC progression. Promote aggressive behaviors in tumor progression Recoding
HNRNPK chr9:86586255 chr9:83971340 Presence NA. Affect disease processing Recoding
CDC14B chr9:96300784 chr9:93538502 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300797 chr9:93538515 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300805 chr9:93538523 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300832 chr9:93538550 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300834 chr9:93538552 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300836 chr9:93538554 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300875 chr9:93538593 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300883 chr9:93538601 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300895 chr9:93538613 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300898 chr9:93538616 Decrease NA Reduce RNA editing in disease NA
CDC14B chr9:96300899 chr9:93538617 Decrease NA Reduce RNA editing in disease NA
HTR2C chrX:114082684 chrX:114848121 Presence Cytokines may induce depression at least in part through their effects on the editing of 5-HT2CR mRNA. Induce disease Recoding
HTR2C chrX:114082686 chrX:114848123 Presence Cytokines may induce depression at least in part through their effects on the editing of 5-HT2CR mRNA. Induce disease Recoding
HTR2C chrX:114082688 chrX:114848125 Presence Cytokines may induce depression at least in part through their effects on the editing of 5-HT2CR mRNA. Induce disease Recoding
HTR2C chrX:114082689 chrX:114848126 Presence Cytokines may induce depression at least in part through their effects on the editing of 5-HT2CR mRNA. Induce disease Recoding
HTR2C chrX:114082697 chrX:114848134 Presence Cytokines may induce depression at least in part through their effects on the editing of 5-HT2CR mRNA. Induce disease Recoding
HTR2C chrX:114082697 chrX:114848134 Presence Cytokines may induce depression at least in part through their effects on the editing of 5-HT2CR mRNA. Induce disease Recoding